Prevention of DNA damage in renal transplantation by losartan and enalapril: The role of renin-angiotensin system polymorphisms

Clinical and Experimental Nephrology

Volumn 12, Issue 1, 2008, Pages 65-73

  Ghorbanihaghjo, Amir ^a   Veisi, Pegah ^a   Argani, Hassan ^a   Aghaeishahsavari, Mohammad ^a   Noroozianavval, Masood ^a   Rashtchizadeh, Nadereh ^a   Mesgari, Mehran ^a   Safa, Javid ^a   Babaei, Hosain ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

DNA damage; Enalapril; Losartan; RAS polymorphisms; Renal transplant

Indexed keywords

BIOLOGICAL MARKER; ENALAPRIL; LOSARTAN; MALONALDEHYDE;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DNA DAMAGE; DNA POLYMORPHISM; DRUG EFFECT; DRUG SAFETY; FEMALE; GENOTYPE; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOLOGICAL MARKERS; CELL CYCLE PROTEINS; DEOXYGUANOSINE; DNA DAMAGE; ENALAPRIL; FEMALE; HUMANS; KIDNEY TRANSPLANTATION; LIPID PEROXIDATION; LOSARTAN; MALE; MALONDIALDEHYDE; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC; PROTEIN-SERINE-THREONINE KINASES; RENIN-ANGIOTENSIN SYSTEM;

EID: 38549126151     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-007-0001-x     Document Type: Article

References (54)

1. Schriner SE, Ogburn CE, Smith AC, Newcomb TG, Ladiges WC, Dolle ME, et al. Levels of dna damage are unaltered in mice overexpressing human catalase in nuclei. Free Radic Bio Med. 2000;29:664-73.
2. Grune T, Davies KJ. Breakdown of oxidized proteins as a part of secondary antioxidant defenses in mammalian cells. Biofactors. 1997;6:165-72.
3. Halliwell B. Why and how should we measure oxidative DNA damage in nutritional studies? How far have we come? Am J Clin Nutr. 2000;72:1082-7.
4. de Groot H. Reactive oxygen species in tissue injury. Hepatogastroenterology. 1994;41:328-32.
5. Basaga HS. Biochemical aspects of free radicals. Biochem Cell Biol. 1990;68:989-98.
6. Floyd RA. Role of oxygen free radicals in carcinogenesis and brain ischemia. FASEB J. 1990;4:2587-97.
7. Fraga CG, Shigenaga MK, Park JW, Degan P, Ames BN. Oxidative damage to DNA during aging: 8-hydroxy-2′-deoxyguanosine in rat organ DNA and urine. Proc Natl Acad Sci USA. 1990;87:4533-7.
8. Mei S, Yao Q, Wu C, Xu G. Determination of urinary 8-hydroxy-2′- deoxyguanosine by two approaches-capillary electrophoresis GC/MS: an assay for in vivo oxidative DNA damage in cancer patients. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;827:83-7.
9. Kuchino Y, Mori F, Kasai H, Inoue H, Iwai S, Miura K, et al. Misreading of DNA templates containing 8-hydroxydeoxyguanosine at the modified base and at adjacent residues. Nature. 1987;327:77-9.
10. Shi M, Takeshita H, Komatsu M, Xu B, Aoyama K, Takeuchi T. Generation of 8-hydroxydeoxyguanosine from DNA using rat liver homogenates. Cancer Sci. 2005;96:13-8.
11. Arnett SD, Osbourn DM, Moore KD, Vandaveer SS, Lunte CE. Determination of 8-oxoguanine and 8-hydroxy-2′-deoxyguanosine in the rat cerebral cortex using microdialysis sampling and capillary electrophoresis with electrochemical detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;827:16-25.
12. Miwa M, Matsumaru H, Akimoto Y, Naito S, Ochi H. Quantitative determination of urinary 8-hydroxy-2′-deoxyguanosine level in healthy Japanese volunteers. Biofactors. 2004;22:249-53.
13. Shigenaga MK, Ames BN. Assays for 8-hydroxy-2′-deoxyguanosine: a biomarker of in vivo oxidative DNA damage. Free Radic Biol Med. 1991;10:211-6.
14. Loft S, Vistisen K, Ewertz M, Tjonneland A, Overvad K, Poulsen HE. Oxidative DNA damage estimated by 8-hydroxydeoxyguanosine excretion in humans: influence of smoking, gender and body mass index. Carcinogenesis. 1992;13:2241-7.
15. Bogdanov MB, Beal MF, McCabe DR, Griffin RM, Matson WR. A carbon column-based liquid chromatography electrochemical approach to routine 8-hydroxy-2′-deoxyguanosine measurements in urine and other biologic matrices: a one-year evaluation of methods. Free Radic Biol Med. 1999;27:647-66.
16. Vural A, Yilmaz MI, Caglar K, Aydin A, Sonmez A, Eyileten T, et al. Assessment of oxidative stress in the early posttransplant period: comparison of cyclosporine A and tacrolimus-based regimens. Am J Nephrol. 2005;25:250-5.
17. Krivosikova Z, Dusinska M, Spustova V, Sebekova K, Blazicek P, Heidland A, et al. DNA damage of lymphocytes in experimental chronic renal failure: beneficial effects of losartan. Kidney Int Suppl. 2001;78:212-5.
18. Mailloux LU, Napolitano B, Bellucci AG, Vernace M, Wilkes BM, Mossey RT. Renal vascular disease causing end-stage renal disease, incidence, clinical correlated, and outcomes: a 20-year clinical experience. Am J Kidney Dis. 1994;24:622-9.
19. Akcay A, Ozdemir FN, Atac FB, Sezer S, Verdi H, Arat Z, et al. Angiotensin-converting enzyme genotype is a predictive factor in the peak panel-reactive antibody response. Transplant Proc. 2004;36:35-7.
20. Yavuz D, Koc M, Toprak A, Akpinar I, Velioglu A, Deyneli O, et al. Effects of ACE inhibition and AT1-receptor antagonism on endothelial function and insulin sensitivity in essential hypertensive patients. J Renin Angiotensin Aldosterone Syst. 2003;4:197-203.
21. Pechter U, Aunapuu M, Riispere Z, Vihalemm T, Kullissaar T, Zilmer K, et al. Oxidative stress status in kidney tissue after losartan and atenolol treatment in experimental renal failure. Nephron Exp Nephrol. 2004;97:33-7.
22. Bayorh MA, Ganafa AA, Eatman D, Walton M, Feuerstein GZ. Simvastatin and losartan enhance nitric oxide and reduce oxidative stress in salt-induced hypertension. Am J Hypertens. 2005;18:1496-502.
23. Khaper N, Singal PK. Modulation of oxidative stress by a selective inhibition of angiotensin II type1 receptors in MI rats. J Am Coll Cardiol. 2001;37:1461-6.
24. Agarwal R. Proinflammatory effects of oxidative stress in chronic kidney disease: role of additional angiotensin II blockade. Am J Physiol Renal Physiol. 2003;284:863-9.
25. Bartosz M, Kedziora J, Bartosz G. Antioxidant and prooxidant properties of captopril and enalapril. Free Radic Bio Med. 1997;23:729-35.
26. Schupp N, Schinzel R, Heidland A, Stopper H. Genotoxicity of advanced glycation end products: involvement of oxidative stress and of angiotensin II type 1 receptors. Ann N Y Acad Sci. 2005;1043:685-95.
27. Hilgers KF, Mann JF. ACE inhibitors versus AT(1) receptor antagonists in patients with chronic renal disease. J Am Soc Nephrol. 2002;13:1100-8.
28. Frishberg Y, Becker-Cohen R, Halle D, Feigin E, Eisenstein B, Halevy R. Genetic polymorphisms of the renin-angiotensin system and the outcome of focal segmental glomerulosclerosis in children. Kidney Int. 1998;54:1843-9.
29. Ohno T, Kawazu S, Tomono S. Association analyses of the polymorphisms of angiotensin-converting enzyme and angiotensinogen genes with diabetic nephropathy in Japanese non-insulin-dependent diabetics. Metabolism. 1996;45:218-22.
30. Toyokuni S, Tanaka T, Hattori Y, Nishiyama Y, Yoshida A, Uchida K, et al. Quantitative immunohistochemical determination of 8-hydroxy-2′- deoxyguanosine by a monoclonal antibody N45.1: its application to ferric nitrilotriacetate-induced renal carcinogenesis model. Lab Invest. 1997;76:365-74.
31. Yagi K. Lipid peroxides in hepatic, gastrointestinal, and pancreatic diseases. Adv Exp Med Biol. 1994;366:165-9.
32. Vaziri ND, Oveisi F, Ding Y. Role of increased oxygen free radical activity in the pathogenesis of uremic hypertension. Kidney Int. 1998;53:1748-54.
33. Collins AR, Dusinska M, Gedik CM, Stetina R. Oxidative damage to DNA: do we have a reliable biomarker? Environ Health Perspect. 1996;104:465-9.
34. Verbeelen DL, De Craemer D, Peeters P, Vanden Houte K, Van den Branden C. Enalapril increases antioxidant enzyme activity in renal cortical tissue of five-sixths-nephrectomized rats. Nephron. 1998;80:214-9.
35. Demple B. Genetic responses against nitric oxide toxicity. Braz J Med Biol Res. 1999;32:1417-27.
36. Vamvakas S, Bahner U, Becker P, Steinle A, Gotz R, Heidland A. Impairment of DNA repair in the course of long-term hemodialysis and under cyclosporine immunosuppression after renal transplantation. Transplant Proc. 1996;28:3468-73.
37. Halliwell B. Can oxidative DNA damage be used as a biomarker of cancer risk in humans? Problems, resolutions and preliminary results from nutritional supplementation studies. Free Radic Res. 1998;29:469-86.
38. Kasai H. Analysis of a form of oxidative DNA damage, 8-hydroxy-2'- deoxyguanosine, as a marker of cellular oxidative stress during carcinogenesis. Mutat Res. 1997;387:147-63.
39. Rehman A, Bourne LC, Halliwell B, Rice-Evans CA. Tomato consumption modulates oxidative DNA damage in humans. Biochem Biophys Res commun. 1999;262:828-31.
40. England T, Beatty E, Rehman A, Nourooz-Zadeh J, Pereira P, O'Reilly J, et al. The steady-state levels of oxidative DNA damage and of lipid peroxidation (F2-isoprostanes) are not correlated in healthy human subjects. Free Radic Res. 2000;32:355-62.
41. van Zeeland AA, de Groot AJ, Hall J, Donato F. 8-Hydroxydeoxyguanosine in DNA from leukocytes of healthy adults: relationship with cigarette smoking, environmental tobacco smoke, alcohol and coffee consumption. Mutat Res. 1999;439:249-57.
42. Bianchini F, Elmstahl S, Martinez-Garcia C, van Kappel AL, Douki T, Cadet J, et al. Oxidative DNA damage in human lymphocytes: correlations with plasma levels of alpha-tocopherol and carotenoids. Carcinogenesis. 2000;21:321-4.
43. Frimat L, Philippe C, Maghakian MN, Jonveaux P, Hurault de Ligny B, et al. Polymorphism of angiotensin converting enzyme, angiotensinogen, and angiotensin II type 1 receptor genes and end-stage renal failure in IgA nephropathy: IGARAS-a study of 274 Men. J Am Soc Nephrol. 2000;11:2062-7.
44. Slowinski T, Diehr P, Kleemann P, Fritsche L, Renders L, Budde K, et al. No association between renin-angiotensin system gene polymorphisms and early and long-term allograft dysfunction in kidney transplant recipients. Nephrol Dial Transplant. 2004;19:2846-51.
45. Nicod J, Richard A, Frey FJ, Ferrari P. Recipient RAS gene variants and renal allograft function. Transplantation. 2002;73:960-5.
46. Boratynska M, Boratynski J, Klinger M, Szyber P, Pawlowski S, Pupka A, et al. Lipid peroxidation and cytokines in chronic allograft failure: influence of nonimmunological risk factors. Transplant Proc. 2000;32:1384-6.
47. Perez Fernandez R, Martin Mateo MC, De Vega L, Bustamante Bustamante J, Herrero M, Bustamante Munguira E. Antioxidant enzyme determination and a study of lipid peroxidation in renal transplantation. Ren Fail. 2002;24:353-9.
48. Scribner AW, Loscalzo J, Napoli C. The effect of angiotensin-converting enzyme inhibition on endothelial function and oxidant stress. Eur J Pharmacol 2003;482:95-9.
49. Strawn WB, Chappell MC, Dean RH, Kivlighn S, Ferrario CM. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation. 2000;101:1586-93.
50. Kramer C, Sunkomat J, Witte J, Luchtefeld M, Walden M, Schmidt B, et al. Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179. Circ Res. 2002;90:770-6.
51. Da Ros R, Assaloni R, Ceriello A. Molecular targets of diabetic vascular complications and potential new drugs. Curr Drug Targets. 2005;6:503-9.
52. Abdi R, Tran TB, Zee R, Brenner BM, Milford EL. Angiotensin gene polymorphism as a determinant of posttransplantation renal dysfunction and hypertension. Transplantation. 2001;72:726-9.
53. Martinez-Alfaro M, Palma-Tirado L, Sandoval-Zapata F, Carabez-Trejo A. Correlation between formamidopyrimidine DNA glycosylase (Fpg)-sensitive sites determined by a comet assay, increased MDA, and decreased glutathione during long exposure to thinner inhalation. Toxicol Lett 2005 (Epub ahead of print).
54. Kocyigit A, Kelaes H, Selek S, Guzel S, Celik H, Erel O. Increased DNA damage and oxidative stress in patients with cutaneous leishmaniasis. Mutat Res. 2005;585:71-8.